Diaceutics (LON:DXRX) Earns Buy Rating from Canaccord Genuity Group

Diaceutics (LON:DXRX)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity Group in a research report issued on Wednesday,Digital Look reports. They presently have a GBX 215 target price on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 63.87% from the stock’s current price.

Diaceutics Stock Performance

Diaceutics stock traded up GBX 4.70 during trading hours on Wednesday, hitting GBX 131.20. The company had a trading volume of 1,928,193 shares, compared to its average volume of 182,702. Diaceutics has a one year low of GBX 125 and a one year high of GBX 180. The firm has a market cap of £111.03 million, a PE ratio of 1,192.73 and a beta of 0.89. The firm has a 50-day moving average of GBX 143.48 and a 200 day moving average of GBX 153.46. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92.

Diaceutics (LON:DXRX) last announced its earnings results on Tuesday, May 26th. The company reported GBX 11 earnings per share for the quarter. The company had revenue of GBX 3,844 million for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. On average, sell-side analysts expect that Diaceutics will post 1.0107919 earnings per share for the current year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.